Brian Zeglis

Title: Innovations by Brian Zeglis in Radioligand Development

Introduction

Brian Zeglis is an accomplished inventor based in New York, NY (US). He has made significant contributions to the field of radioligands, particularly in the context of pretargeted PET imaging. With a total of 2 patents, his work focuses on enhancing imaging strategies for cancer detection.

Latest Patents

Zeglis's latest patents include "Radioligands for pretargeted PET imaging and methods of their therapeutic use." This patent describes Tz/TCO-based pretargeting strategies utilizing an Al[F]-NOTA-labeled tetrazine radioligand. This innovative imaging strategy allows for the delineation of cancer at earlier time points compared to traditional imaging methods. Additionally, it reduces the radiation dose to healthy tissues when compared to directly labeled antibodies. Another notable patent is for a "Reagent for site-selective bioconjugation of proteins or antibodies." This invention features a label for antibodies or proteins that is both site-selective and unusually stable in vivo, with a general formula that includes a metal chelator, a fluorophore, or a click-chemistry synthon.

Career Highlights

Throughout his career, Brian Zeglis has worked with prestigious institutions such as Memorial Sloan Kettering Cancer Center and City University of New York. His experience in these organizations has allowed him to collaborate with leading experts in the field.

Collaborations

Some of his notable coworkers include Jason S. Lewis and Thomas Reiner. Their collaborative efforts have contributed to advancements in radioligand research and development.

Conclusion

Brian Zeglis's innovative work in radioligands has the potential to significantly impact cancer imaging and treatment. His patents reflect a commitment to improving medical technologies and patient outcomes.